Angioimmunoblastic T-Cell Lymphoma / Nodal TFH-cell lymphoma · line 2 · Romidepsin IV days 1, 8, 15 q28d — r/r PTCL incl AITL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-ROMIDEPSIN-PTCL |
| ID | IND-AITL-2L-ROMIDEPSIN |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AITL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L+ for r/r AITL. NCCN-listed despite FDA PTCL indication withdrawal. ECG ST/T changes during infusion typically benign — distinguish from ischemic via baseline + serial ECGs. UA access barrier dominant.
Used By
Algorithms
ALGO-AITL-2L- ALGO-AITL-2L